Insulin resistance and lower plasma adiponectin increase malignancy risk in nondiabetic continuous ambulatory peritoneal dialysis patients

Jung Tak Park, Tae Hyun Yoo, Tae Ik Chang, Dong Hyung Lee, Joo Hyun Lee, Jung Eun Lee, Hoon Young Choi, Shin Wook Kang, Dae Suk Han, Dong Ryeol Ryu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

End-stage renal disease patients have a higher risk for developing cancer. Although several causes for this increased risk have been proposed, the risk factors for cancer development in this population have not been elucidated. The aim of this study was to determine whether metabolic derangements, including insulin resistance and altered adipokines, increase the risk of developing malignancies in peritoneal dialysis (PD) patients, who are vulnerable to metabolic disorders because of excessive glucose absorbed from the dialysate. Study subjects comprised 106 nondiabetic PD patients who had been on PD for a minimum of 3 months with no overt malignancy. Baseline anthropometry, fasting glucose, insulin, and adiponectin were measured. The development of malignancy was evaluated during the follow-up period. During the mean follow-up of 47.0 ± 23.7 months, malignancy occurred in 15 patients (14.2%). The most common site of cancer was the kidney (26.7%), followed by thyroid (13.3%) and stomach (13.3%). Baseline insulin levels and homeostasis model assessment of insulin resistance were significantly higher, whereas plasma adiponectin levels were significantly lower, in patients who developed malignancy. Cox proportional hazards analysis revealed that insulin levels, homeostasis model assessment of insulin resistance, and lower adiponectin were independent predictors of malignancy. These findings demonstrate that insulin resistance and lower adiponectin levels could be risk factors for malignancy in nondiabetic PD patients.

Original languageEnglish
Pages (from-to)121-126
Number of pages6
JournalMetabolism: Clinical and Experimental
Volume60
Issue number1
DOIs
Publication statusPublished - 2011 Jan 1

Fingerprint

Continuous Ambulatory Peritoneal Dialysis
Adiponectin
Insulin Resistance
Peritoneal Dialysis
Neoplasms
Insulin
Homeostasis
Glucose
Anthropometry
Adipokines
Kidney Neoplasms
Dialysis Solutions
Chronic Kidney Failure
Fasting
Stomach
Thyroid Gland

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Park, Jung Tak ; Yoo, Tae Hyun ; Chang, Tae Ik ; Lee, Dong Hyung ; Lee, Joo Hyun ; Lee, Jung Eun ; Choi, Hoon Young ; Kang, Shin Wook ; Han, Dae Suk ; Ryu, Dong Ryeol. / Insulin resistance and lower plasma adiponectin increase malignancy risk in nondiabetic continuous ambulatory peritoneal dialysis patients. In: Metabolism: Clinical and Experimental. 2011 ; Vol. 60, No. 1. pp. 121-126.
@article{291cfde0155a4d1c81b38a124dc3bf39,
title = "Insulin resistance and lower plasma adiponectin increase malignancy risk in nondiabetic continuous ambulatory peritoneal dialysis patients",
abstract = "End-stage renal disease patients have a higher risk for developing cancer. Although several causes for this increased risk have been proposed, the risk factors for cancer development in this population have not been elucidated. The aim of this study was to determine whether metabolic derangements, including insulin resistance and altered adipokines, increase the risk of developing malignancies in peritoneal dialysis (PD) patients, who are vulnerable to metabolic disorders because of excessive glucose absorbed from the dialysate. Study subjects comprised 106 nondiabetic PD patients who had been on PD for a minimum of 3 months with no overt malignancy. Baseline anthropometry, fasting glucose, insulin, and adiponectin were measured. The development of malignancy was evaluated during the follow-up period. During the mean follow-up of 47.0 ± 23.7 months, malignancy occurred in 15 patients (14.2{\%}). The most common site of cancer was the kidney (26.7{\%}), followed by thyroid (13.3{\%}) and stomach (13.3{\%}). Baseline insulin levels and homeostasis model assessment of insulin resistance were significantly higher, whereas plasma adiponectin levels were significantly lower, in patients who developed malignancy. Cox proportional hazards analysis revealed that insulin levels, homeostasis model assessment of insulin resistance, and lower adiponectin were independent predictors of malignancy. These findings demonstrate that insulin resistance and lower adiponectin levels could be risk factors for malignancy in nondiabetic PD patients.",
author = "Park, {Jung Tak} and Yoo, {Tae Hyun} and Chang, {Tae Ik} and Lee, {Dong Hyung} and Lee, {Joo Hyun} and Lee, {Jung Eun} and Choi, {Hoon Young} and Kang, {Shin Wook} and Han, {Dae Suk} and Ryu, {Dong Ryeol}",
year = "2011",
month = "1",
day = "1",
doi = "10.1016/j.metabol.2010.02.006",
language = "English",
volume = "60",
pages = "121--126",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "1",

}

Insulin resistance and lower plasma adiponectin increase malignancy risk in nondiabetic continuous ambulatory peritoneal dialysis patients. / Park, Jung Tak; Yoo, Tae Hyun; Chang, Tae Ik; Lee, Dong Hyung; Lee, Joo Hyun; Lee, Jung Eun; Choi, Hoon Young; Kang, Shin Wook; Han, Dae Suk; Ryu, Dong Ryeol.

In: Metabolism: Clinical and Experimental, Vol. 60, No. 1, 01.01.2011, p. 121-126.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Insulin resistance and lower plasma adiponectin increase malignancy risk in nondiabetic continuous ambulatory peritoneal dialysis patients

AU - Park, Jung Tak

AU - Yoo, Tae Hyun

AU - Chang, Tae Ik

AU - Lee, Dong Hyung

AU - Lee, Joo Hyun

AU - Lee, Jung Eun

AU - Choi, Hoon Young

AU - Kang, Shin Wook

AU - Han, Dae Suk

AU - Ryu, Dong Ryeol

PY - 2011/1/1

Y1 - 2011/1/1

N2 - End-stage renal disease patients have a higher risk for developing cancer. Although several causes for this increased risk have been proposed, the risk factors for cancer development in this population have not been elucidated. The aim of this study was to determine whether metabolic derangements, including insulin resistance and altered adipokines, increase the risk of developing malignancies in peritoneal dialysis (PD) patients, who are vulnerable to metabolic disorders because of excessive glucose absorbed from the dialysate. Study subjects comprised 106 nondiabetic PD patients who had been on PD for a minimum of 3 months with no overt malignancy. Baseline anthropometry, fasting glucose, insulin, and adiponectin were measured. The development of malignancy was evaluated during the follow-up period. During the mean follow-up of 47.0 ± 23.7 months, malignancy occurred in 15 patients (14.2%). The most common site of cancer was the kidney (26.7%), followed by thyroid (13.3%) and stomach (13.3%). Baseline insulin levels and homeostasis model assessment of insulin resistance were significantly higher, whereas plasma adiponectin levels were significantly lower, in patients who developed malignancy. Cox proportional hazards analysis revealed that insulin levels, homeostasis model assessment of insulin resistance, and lower adiponectin were independent predictors of malignancy. These findings demonstrate that insulin resistance and lower adiponectin levels could be risk factors for malignancy in nondiabetic PD patients.

AB - End-stage renal disease patients have a higher risk for developing cancer. Although several causes for this increased risk have been proposed, the risk factors for cancer development in this population have not been elucidated. The aim of this study was to determine whether metabolic derangements, including insulin resistance and altered adipokines, increase the risk of developing malignancies in peritoneal dialysis (PD) patients, who are vulnerable to metabolic disorders because of excessive glucose absorbed from the dialysate. Study subjects comprised 106 nondiabetic PD patients who had been on PD for a minimum of 3 months with no overt malignancy. Baseline anthropometry, fasting glucose, insulin, and adiponectin were measured. The development of malignancy was evaluated during the follow-up period. During the mean follow-up of 47.0 ± 23.7 months, malignancy occurred in 15 patients (14.2%). The most common site of cancer was the kidney (26.7%), followed by thyroid (13.3%) and stomach (13.3%). Baseline insulin levels and homeostasis model assessment of insulin resistance were significantly higher, whereas plasma adiponectin levels were significantly lower, in patients who developed malignancy. Cox proportional hazards analysis revealed that insulin levels, homeostasis model assessment of insulin resistance, and lower adiponectin were independent predictors of malignancy. These findings demonstrate that insulin resistance and lower adiponectin levels could be risk factors for malignancy in nondiabetic PD patients.

UR - http://www.scopus.com/inward/record.url?scp=78649952873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649952873&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2010.02.006

DO - 10.1016/j.metabol.2010.02.006

M3 - Article

C2 - 20303125

AN - SCOPUS:78649952873

VL - 60

SP - 121

EP - 126

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 1

ER -